Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Elevated endogenous cannabinoids in schizophrenia.

Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D.

Neuroreport. 1999 Jun 3;10(8):1665-9.

PMID:
10501554
2.

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D.

Schizophr Res. 2007 Aug;94(1-3):29-36.

PMID:
17566707
3.

Endocannabinoids in chronic migraine: CSF findings suggest a system failure.

Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P.

Neuropsychopharmacology. 2007 Jun;32(6):1384-90. Erratum in: Neuropsychopharmacology. 2007 Jun;32(6):1432.

4.

Control of pain initiation by endogenous cannabinoids.

Calignano A, La Rana G, Giuffrida A, Piomelli D.

Nature. 1998 Jul 16;394(6690):277-81.

PMID:
9685157
5.

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.

Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D.

Neuropsychopharmacology. 2004 Nov;29(11):2108-14.

6.

Anandamide dysfunction in prodromal and established psychosis.

Leweke FM.

Curr Pharm Des. 2012;18(32):5188-93. Review.

PMID:
22716147
7.

Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines.

Fontana A, Di Marzo V, Cadas H, Piomelli D.

Prostaglandins Leukot Essent Fatty Acids. 1995 Oct;53(4):301-8.

PMID:
8577784
8.

Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.

Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E.

J Psychopharmacol. 2008 May;22(3):262-9. doi: 10.1177/0269881107083816.

PMID:
18308802
9.

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.

Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Piomelli D, Leweke FM.

Br J Psychiatry. 2009 Apr;194(4):371-2. doi: 10.1192/bjp.bp.108.053843. Erratum in: Br J Psychiatry. 2011 Jun; 198(6):495.

10.

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.

Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D.

Nat Neurosci. 1999 Apr;2(4):358-63.

PMID:
10204543
11.

Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture.

Maccarrone M, Attinà M, Cartoni A, Bari M, Finazzi-Agrò A.

J Neurochem. 2001 Jan;76(2):594-601.

12.

Plasma anandamide and related n-acylethanolamide levels are not elevated in pregnancies complicated by hyperemesis gravidarum.

Gebeh AK, Willets JM, Marczylo TH, Konje JC.

J Matern Fetal Neonatal Med. 2014 Jun;27(9):954-9. doi: 10.3109/14767058.2013.847413.

PMID:
24117326
13.

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes.

Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V.

J Biol Chem. 1997 Feb 7;272(6):3315-23.

15.

Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.

Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G.

Nature. 1997 Dec 4;390(6659):518-21.

PMID:
9394002
16.

Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.

Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D.

Eur J Pharmacol. 2000 Nov 17;408(2):161-8.

PMID:
11080522
17.
18.

Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.

Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A.

Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80.

19.

Cannabinoid/anandamide system and schizophrenia: is there evidence for association?

Schneider U, Leweke FM, Mueller-Vahl KR, Emrich HM.

Pharmacopsychiatry. 1998 Jul;31 Suppl 2:110-3.

PMID:
9754842
20.

The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.

Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M, Casellas P.

FEBS Lett. 1998 Apr 3;425(3):419-25.

Supplemental Content

Support Center